Lv2
187 积分 2025-03-06 加入
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
2个月前
已完结
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
2个月前
已完结
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
3个月前
已完结
Targeting B Cells and Plasma Cells in Glomerular Disease
3个月前
已完结
Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
4个月前
已完结
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
4个月前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study
5个月前
已完结
皖公网安备34019202002308
